Amgen Inc. Restructuring and Related Cost, Accelerated Depreciation
Amgen Inc. (AMGN) reported Restructuring and Related Cost, Accelerated Depreciation of $100.00 million for the 12-month period ending 2015-12-31, per its 10-K filed 2018-02-13.
Discontinued › Notes
us-gaap:RestructuringReserveAcceleratedDepreciation · last filed 2018-02-13
- Amgen Inc. restructuring and related cost, accelerated depreciation for the quarter ending 2015-12-31 was $25.00M.
- Amgen Inc. restructuring and related cost, accelerated depreciation for the quarter ending 2015-09-30 was $22.00M, a 24.14% decline year-over-year.
- Amgen Inc. restructuring and related cost, accelerated depreciation for the quarter ending 2015-06-30 was $25.00M.
- Amgen Inc. restructuring and related cost, accelerated depreciation for the quarter ending 2015-03-31 was $28.00M.
- Amgen Inc. restructuring and related cost, accelerated depreciation for fiscal 2015 was $100.00M, a 81.82% increase from fiscal 2014.
- Amgen Inc. restructuring and related cost, accelerated depreciation for fiscal 2014 was $55.00M.
| Period end | Restructuring and Related Cost, Accelerated Depreciation 3 month | Restructuring and Related Cost, Accelerated Depreciation 6 month | Restructuring and Related Cost, Accelerated Depreciation 9 month | Restructuring and Related Cost, Accelerated Depreciation 12 month |
|---|---|---|---|---|
| 2015-12-31 | $25.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $47.00M derived: sum of 2 quarters · filed 2018-02-13 | $72.00M derived: sum of 3 quarters · filed 2018-02-13 | $100.00M 10-K · filed 2018-02-13 |
| 2015-09-30 | $22.00M 10-Q · filed 2015-11-02 | $47.00M derived: sum of 2 quarters · filed 2015-11-02 | $75.00M 10-Q · filed 2015-11-02 | |
| 2015-06-30 | $25.00M 10-Q · filed 2015-08-05 | $53.00M 10-Q · filed 2015-08-05 | ||
| 2015-03-31 | $28.00M 10-Q · filed 2015-04-27 | |||
| 2014-12-31 | $55.00M 10-K · filed 2018-02-13 | |||
| 2014-09-30 | $29.00M 10-Q · filed 2014-10-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |